Arrayit Corporation (ARYC)

[StockDetective]

Julie Taguchi in the background with Todd Martinsky making that sweet discovery?

Julie Taguchi specializes in ovarian cancer.

https://www.instagram.com/p/BgMsxken3yb/

https://www.google.com/search?q=julie+taguchi&client=safari&hl=en-us&prmd=inv&source=lnms&tbm=isch&sa=X&ved=2ahUKEwjwtJ-EqrXgAhVSHjQIHY5oCeIQ_AUoAXoECAwQAQ&biw=414&bih=622#imgrc=1H3fz3l-kKvjZM


Repost from the sticky:

I also asked about the OvaDx product and was advised that the details of the test were confidential at the time. As I pressed the issue a bit further was told that there was going to be a press release in the future regarding the matter. The subject was then changed as the good doctor advised me that he had said too much already.

When i finally viewed my allergy test report, which is almost identical to the Allergenex report besides it stating Arrayit on top (see sample report)...

https://allergyfreesolutions.com/item/sample-reports/

The name Dr Julie A. Taguchi showed up as the lab director of Arrayit. The report also comes with Arrayit’s CLIA laboratory number. But wait... Dr Julie A. Taguchi is also described on the OvaDx product details down below and also has ties to Kaiser Permanente.



From the website:

Can ovarian cancer be cured by early stage detection and treatment?

Yes. According to Dr. Julie A. Taguchi, MD, of the Sansum Medical Clinic in Santa Barbara, CA, surgical removal of stage IA ovarian tumors effectively cures ovarian cancer in a large percentage of patients without the requirement for chemotherapy. According to the medical literature, the 20-year survival rate for stage IA patients is very good.

http://www.arrayit.com/Microarray_Diagnostics/Ovarian_Cancer_Forum/ovarian_cancer_forum.html

Doctors and nurses currently use 15 million CA-125 tests per year to monitor ovarian cancer, generating approximately $2 billion in worldwide revenue. Capturing 1% of the ovarian cancer monitoring market would generate $97.5 million in annual revenues for Arrayit through the manufacture and sale of 150,000 OvaDx® tests at $650 per test. Our Sunnyvale laboratories have more than adequate capacity to process 150,000 OvaDx® tests per year upon FDA approval.

This website was updated last year.

In Development

Arrayit Corporation and Avant Diagnostics, Inc. provide the market’s first large panel biomarker monitoring test for ovarian cancer (OVC). OvaDx® is advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.

http://arrayit.com/Microarray_Diagnostics/OvaDx_Ovarian_Cancer_Test/ovadx_ovarian_cancer_test.html